---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005076"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:08:44.756641+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arbutus Q2 net income $2.5M; revenue $10.7M; Dr. Sawhney joins Board

## Summary
- Q2 net income of $2.5M ($0.01 per share) vs loss of $19.8M in Q2 2024; total revenue $10.7M, up from $1.7M.
- Revenue increase primarily due to recognition of deferred revenue from termination of Qilu partnership; cash and equivalents $98.1M.
- Dr. Roger Sawhney appointed to Board effective Aug 4, 2025, succeeding Anuj Hasija who resigned to join Vertex.
- In Moderna U.S. litigation, summary judgment phase began July 2025; jury trial scheduled March 2026.
- R&D expenses down to $5.5M from $15.6M due to restructuring; G&A down to $3.3M from $7.5M.

## SEC filing metadata
- accession: 0001171843-25-005076
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325005076/0001171843-25-005076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325005076/f8k_080625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005076
- JSON: https://secwatch.observer/filing/0001171843-25-005076.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.